Meeting
2020 ASCO Virtual Scientific Program
Immune phenotype and response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC).
Authors
Clinton Yam
The University of Texas MD Anderson Cancer Center, Houston, TX
Clinton Yam , Gheath Alatrash , Er-Yen Yen , Haven Garber , Anne V. Philips , Lei Huo , Fei Yang , Roland L. Bassett Jr., Xiangjie Sun , Edwin Roger Parra Cuentas , William Fraser Symmans , Sahil Seth , Jason B White , Gaiane M Rauch , Senthil Damodaran , Jennifer Keating Litton , Jennifer Ann Wargo , Gabriel N. Hortobagyi , Stacy L. Moulder , Elizabeth A. Mittendorf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 38: 2020 (suppl; abstr 509)
DOI
10.1200/JCO.2020.38.15_suppl.509
Abstract #
509
Poster Bd #
1
Abstract Disclosures
Funded by Conquer Cancer
Similar Posters
Poster
2021 ASCO Annual Meeting
The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC).
First Author: Nour Abuhadra
Poster
2019 ASCO Annual Meeting
Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443).
First Author: Sahil Seth
Poster
2019 ASCO Annual Meeting
Phase II trial of nivolumab with chemotherapy as neoadjuvant treatment in inflammatory breast cancer.
First Author: Maryann J. Kwa
Poster
2024 ASCO Annual Meeting
Neoadjuvant hypofractionated radiotherapy combined with pembrolizumab plus chemotherapy for potentially resectable non-small cell lung cancer: A phase Ib study.
First Author: Naixin Ding